EXECUTIVE BOARD

Notice no.: 5/2007



Danisco A/S Langebrogade 1 P.O. Box 17 1001 Copenhagen K Denmark Tel. +45 3266 2000

Fax +45 3266 2000 Fax +45 3266 2175 www.danisco.com info@danisco.com

17 April 2007

Patent dispute over SPEZYME® ETHYL settled as expected

A settlement has been reached on the level of reasonable legal costs, incurred prejudgment interest etc. in the patent dispute over SPEZYME® ETHYL (see Stock Exchange Notice no. 2/2007 of 19 February 2007). Accordingly, Novozymes A/S will receive a total payment of USD 15.3 million inclusive of patent infringement damages of USD 8.2 million.

Concurrently, the parties have concluded an agreement on reciprocal waiving of the right to appeal the decision of the court of first instance and have agreed not to publish any details of the settlement.

The total amount, which is due for immediate payment, will not have an impact on earnings expectations for 2006/07 as provision was previously made for the amount.

Danisco releases its results for the financial year 2006/07 on 20 June 2007.

Yours faithfully

Tom Knutzen CEO

For further information, please contact:

Investor Relations, Danisco A/S, tel. +45 3266 2912 Media Relations, Danisco A/S, tel. +45 3266 2913

With 10,500 employees in more than 40 countries, Danisco is one of the world's leading producers of food ingredients, sugar and industrial bioproducts. Based on our technology platform we use nature's own raw materials and resources to develop and produce ingredients for food and other products used in everyday life. Danisco ingredients are used in about every second ice cream and cheese, every third box of detergent and every fourth loaf of bread produced globally. Being based on food technology and biotechnology solutions, Danisco's ingredients are also used in other consumer products – from feed and toothpaste to biofuel and plastics. Throughout the value chain, sustainability is integrated in Danisco's way of doing business.